Incyte hopes to sneak Zynyz through the back door
In first-line NSCLC the drug beats chemo, and not Keytruda.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Merck & Co gets in on the bispecific act
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
SITC 2024 – Arcus springs a TIGIT surprise
Reports of Arc-10's failure are greatly exaggerated, the company argues.
